임상 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Clinical Diagnostics Market Growth & Trends:

The global clinical diagnostics market size is expected to reach USD 169.23 billion by 2030, registering a CAGR of 6.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is propelled by the growing incidence of chronic diseases, the creation of specialized tests for early detection and disease management, and the rising demand for laboratory automation. Additionally, the rapid adoption of point-of-care diagnostic products has introduced a trend towards decentralization in the healthcare industry. Further growth is driven by increased government investments and ongoing R&D efforts.

The prevalence of chronic conditions, such as cardiovascular diseases, diabetes, cancer, and respiratory disorders, pose a substantial burden on healthcare systems worldwide. Early and accurate diagnosis plays a crucial role in managing these diseases effectively, leading to an increased demand for advanced diagnostic tools and technologies. Early detection and accurate staging of cancer are crucial for successful treatment outcomes. Clinical diagnostics play a vital role in cancer screening, diagnosis, and monitoring through various techniques, including imaging tests (CT scans, MRI, PET scans), molecular diagnostics (genetic testing, liquid biopsies), and immunoassays for tumor markers. Furthermore, the introduction of new products in the field of infectious disease testing is contributing to the market's growth. For instance, in March 2021 FDA's Emergency Use Authorization (EUA) granted BinaxNOW COVID-19 Ag Card rapid test by Abbott's. This lateral flow immunoassay is designed for the rapid detection of COVID-19, and its availability is expected to increase demand for infectious disease testing products.

The market is undergoing a rapid transformation as it adopts automation technologies to streamline operations, enhance accuracy, and reduce turnaround time. Automation minimizes the risk of errors and improves the precision and accuracy of results, while also enabling the handling of large volumes of samples, resulting in increased throughput. The introduction of innovative automated point-of-care (POC) analyzers is expected to drive increased adoption, offering cost-effective testing and the ability to conduct multiple tests simultaneously. As a result, there has been a notable trend towards adopting novel products, which has been accelerated by the pandemic and the increased availability of advanced diagnostic instruments that support novel assays.

The demand for cost-effective automated immunoassay systems is on the rise, particularly in developing markets, where there is a growing need for efficient and reliable diagnostic solutions. For instance, in July 2023, Sysmex Corporation introduced a new fully automated and high-speed chemiluminescence immunoassay system in Sysmex AACC exhibition. The integration of security software and Laboratory Information Systems (LIS) with immunoassay analyzers enables administrators to control user access levels and transfer data to other devices, facilitating seamless data transfer and cloud computing. These advancements are expected to drive the growth of the segment over the forecast period.

Presence of government funding programs aimed at reducing the burden of chronic diseases, by funding various clinical trials aimed at, is expected to have a positive impact on the market, In addition governments are allocating substantial funds for research and development (R&D) in the field of clinical diagnostics. In addition, the availability of affordable diagnostic tests for chronic diseases such as AIDS and hepatitis C. Additionally, the rising demand for healthcare services in emerging markets, particularly China and India, where there is a significant unmet need for clinical testing, presents a lucrative opportunity for growth in the clinical diagnostics industry.

Some of the key players in the market are Abbott, Becton Dickinson (BD), Siemens Healthineers, Mindray Medical International Limited, F. Hoffmann-La Roche Ltd, Sysmex Corporation, Bio-Rad Laboratories, and Quest Diagnostics Incorporated. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in May 2023, Becton Dickinson (BD) received FDA 510(k) clearance for its BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application, which leverages artificial intelligence (AI) software. This innovation is expected to significantly reduce the turnaround time for test results, making it a valuable addition to the market for infectious disease testing.

Clinical Diagnostics Market Report Highlights:

• Based on product, instruments accounted for the largest revenue share in 2023. Instruments play a crucial role in enabling healthcare professionals to detect and monitor diseases, guide treatment decisions, and ultimately improve patient outcomes.
• Based on application, infectious diseases dominated the market and accounted for the largest share in 2023.This can be attributed to increasing innovation and availability of specialized test kits for infectious disease detection.
• Based on end use, hospital segment dominated the end use segments with the largest market share in 2023. This is attributable to growing clinical diagnostics demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, detecting illegal drug use, protein analysis, blood typing and monitoring therapeutic drug levels.
• North America dominated the global market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like diabetes, obesity, and respiratory conditions. These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies.
• Asia Pacific is expected to witness the fastest CAGR of 9.0% from 2024 to 2030, due to presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Instruments
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increase in prevalence of chronic diseases
    • 3.2.1.2. Increasing demand for lab automation
    • 3.2.1.3. Development of specialized tests for early disease management
    • 3.2.1.4. Rapid growth of point of care diagnostic products
    • 3.2.1.5. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Clinical Diagnostics Instruments
• 3.3. Clinical Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Clinical Diagnostics Market: Instruments Estimates & Trend Analysis

• 4.1. Instruments Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Clinical Diagnostics Market by Instruments Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Blood gas analyzers
    • 4.5.2.1. Blood gas analyzers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Hematology analyzers
    • 4.5.3.1. Hematology analyzers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Clinical chemistry analyzers
    • 4.5.4.1. Clinical chemistry analyzers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. Urine analyzers
    • 4.5.5.1. Urine analyzers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Coagulation analyzers
    • 4.5.6.1. Coagulation analyzers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.7. Microscopes
    • 4.5.7.1. Microscopes market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.8. Flow Cytometers
    • 4.5.8.1. Flow cytometers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.9. PCR
    • 4.5.9.1. PCR market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.10. Sequencing Instruments
    • 4.5.10.1. Sequencing Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.11. ELISA
    • 4.5.11.1. ELISA market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.12. Mass Spectrometers
    • 4.5.12.1. Mass Spectrometers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.13. Automated Plate Readers
    • 4.5.13.1. Automated plate readers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.14. Spectrophotometers
    • 4.5.14.1. Spectrophotometers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.15. Centrifuges
    • 4.5.15.1. Centrifuges market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.16. Electrophoresis Reagents
    • 4.5.16.1. Electrophoresis equipment market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.17. Point-of-Care Testing (POCT) Devices
    • 4.5.17.1. Point-of-Care testing (POCT) devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.18. Ultrasound Machines
    • 4.5.18.1. Ultrasound machines market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.19. CT (Computed Tomography) Scanners
    • 4.5.19.1. CT (Computed Tomography) scanners market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.20. MRI
    • 4.5.20.1. MRI market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.21. X-ray Machines
    • 4.5.21.1. X-ray Machines market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.22. Others
    • 4.5.22.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Reagents
  • 4.6.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Taq polymerase
    • 4.6.2.1. Taq polymerase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. MMLV RT
    • 4.6.3.1. MMLV RT market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.4. HIV RT
    • 4.6.4.1. HIV RT market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.5. Hot start Taq polymerase
    • 4.6.5.1. Hot start Taq polymerase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.6. UNG
    • 4.6.6.1. UNG market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.7. RNase inhibitors
    • 4.6.7.1. RNase inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.8. Bst polymerase
    • 4.6.8.1. Bst polymerase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.9. PCR master mix
    • 4.6.9.1. PCR master mix market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.10. T7 RNA polymerase
    • 4.6.10.1. T7 RNA polymerase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.11. Cas9 enzyme
    • 4.6.11.1. Cas9 enzyme market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.12. Acid Phosphatase
    • 4.6.12.1. Acid Phosphatase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.13. Alanine aminotransferase
    • 4.6.13.1. Alanine aminotransferase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.14. Amylase
    • 4.6.14.1. Amylase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.15. Angiotensin converting enzyme
    • 4.6.15.1. Angiotensin converting enzyme market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.16. Aspartate aminotransferase
    • 4.6.16.1. Aspartate aminotransferase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.17. Cholinesterase
    • 4.6.17.1. Cholinesterase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.18. Creatinine kinase
    • 4.6.18.1. Creatinine kinase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.19. Gamma glutamyl transferase
    • 4.6.19.1. Gamma glutamyl transferase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.20. Lactate dehydrogenase
    • 4.6.20.1. Lactate dehydrogenase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.21. Renin
    • 4.6.21.1. Renin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.22. Glucose oxidase/glucose dehydrogenase
    • 4.6.22.1. Glucose oxidase/glucose dehydrogenase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.23. Urease
    • 4.6.23.1. Urease market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.24. Amylase
    • 4.6.24.1. Amylase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.25. Lactate oxidase
    • 4.6.25.1. Lactate oxidase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.26. Horseradish peroxide
    • 4.6.26.1. Horseradish peroxide market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.27. Glutamate Oxidase
    • 4.6.27.1. Glutamate Oxidase market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.28. Others
    • 4.6.28.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Software and Services
  • 4.7.1. Software and Services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. Laboratory information management systems
    • 4.7.2.1. Laboratory information management systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. Diagnostic imaging software
    • 4.7.3.1. Diagnostic imaging software market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.4. Data analysis software
    • 4.7.4.1. Data analysis software market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.5. In Vitro Diagnostics Quality Control
    • 4.7.5.1. In Vitro Diagnostics Quality Control market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Kits and assays
  • 4.8.1. Kits and assays market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Clinical Diagnostics Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Clinical Diagnostics Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Infectious Disease
  • 5.5.1. Infectious disease market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. HIV
    • 5.5.2.1. HIV Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Clostridium Difficile
    • 5.5.3.1. Clostridium Difficile Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. HBV
    • 5.5.4.1. HBV Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Respiratory Syncytial Virus (RSV)
    • 5.5.5.1. Respiratory Syncytial Virus (RSV) Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Pneumonia or Streptococcus Associated Infections
    • 5.5.6.1. Respiratory Syncytial Virus (RSV) Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.7. Influenza/Flu
    • 5.5.7.1. Influenza/Flu Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.8. HCV
    • 5.5.8.1. HCV Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.9. MRSA
    • 5.5.9.1. MRSA Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.10. TB and Drug-resistant TB
    • 5.5.10.1. TB and Drug-resistant TB Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.11. HSV
    • 5.5.11.1. HSV Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.12. COVID-19
    • 5.5.12.1. COVID-19 Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.13. Other Infectious Diseases
    • 5.5.13.1. Other Infectious Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Breast Cancer
    • 5.6.2.1. Breast Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. Colorectal Cancer
    • 5.6.3.1. Colorectal Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Cervical Cancer
    • 5.6.4.1. Cervical Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. Lung Cancer
    • 5.6.5.1. Lung Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Prostate Cancer
    • 5.6.6.1. Prostate Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.7. Skin Cancer
    • 5.6.7.1. Skin Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.8. Blood Cancer
    • 5.6.8.1. Blood Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.9. Kidney Cancer
    • 5.6.9.1. Kidney Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.10. Liver Cancer
    • 5.6.10.1. Liver Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.11. Pancreatic Cancer
    • 5.6.11.1. Pancreatic cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.12. Ovarian Cancer
    • 5.6.12.1. Ovarian Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.13. Others
    • 5.6.13.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Cardiology
  • 5.7.1. Cardiology Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Endocrinology
  • 5.8.1. Endocrinology Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Nephrology
  • 5.9.1. Nephrology Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Autoimmune Diseases
  • 5.10.1. Autoimmune Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.11. Hematology
  • 5.11.1. Hematology Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.12. Toxicology
  • 5.12.1. Toxicology Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.13. Cardiology
  • 5.13.1. Cardiology Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.14. Neurology
  • 5.14.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Clinical Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Clinical Diagnostics Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals & Clinics
  • 6.5.1. Hospitals & Clinics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Inpatient and Outpatient
    • 6.5.2.1. Inpatient and Outpatient Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Emergency Rooms
    • 6.5.3.1. Emergency Rooms Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Diagnostic Laboratories
  • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Independent Laboratories
    • 6.6.2.1. Independent Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Reference Laboratories
    • 6.6.3.1. Reference Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Home Care Settings
  • 6.7.1. Home Care Settings Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. At-home Testing Kits
    • 6.7.2.1. At-home Testing Kits Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Point-of-Care Devices
    • 6.7.3.1. Point-of-Care Devices Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Public Health Screening Programs
  • 6.8.1. Public Health Screening Programs Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Clinical Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific: SWOT Analysis
  • 7.7.2. Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Abbott
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Services benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. bioMerieux SA
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Services benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. QuidelOrtho Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Services benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Siemens Healthineers AG
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Services benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Thermo Fisher Scientific, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Services benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Agilent Technologies, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Services benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Bio-Rad Laboratories, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Services benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Qiagen
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Services benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Sysmex Corporation
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Services benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Charles River Laboratories
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Services benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Quest Diagnostics Incorporated
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Services benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. BD.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Services benchmarking
    • 8.3.15.4. Strategic initiatives